These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19431086)

  • 1. Non-Antibody Protein Therapeutics Development & Production--IBC Conference. Successful strategies for bringing protein therapeutics to market.
    Thorne B
    IDrugs; 2009 May; 12(5):271-4. PubMed ID: 19431086
    [No Abstract]   [Full Text] [Related]  

  • 2. Advancing protein therapeutics: current challenges in protein therapeutics -- CHI's Second Annual Conference.
    He M
    IDrugs; 2006 Mar; 9(3):177-8. PubMed ID: 16523380
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody Engineering & Design 2010. 24-25 February 2010, Frankfurt, Germany.
    Beck A
    IDrugs; 2010 May; 13(5):295-9. PubMed ID: 20432182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and manufacture of monoclonal antibodies for radioimmunotherapy.
    Hale G; Berrie E; Bird P
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to current and future protein therapeutics: a protein engineering perspective.
    Carter PJ
    Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical proteins: opportunities and challenges.
    Birch JR; Onakunle Y
    Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
    [No Abstract]   [Full Text] [Related]  

  • 7. CD20 blockers eye crowded rheumatology market.
    Mack GS
    Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
    [No Abstract]   [Full Text] [Related]  

  • 8. A dose of reality for rational therapies.
    Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: biopharmaceutical technologies.
    Jungbauer A
    Biotechnol J; 2007 Jun; 2(6):647. PubMed ID: 17570696
    [No Abstract]   [Full Text] [Related]  

  • 10. Research & market strategy: how choice of drug discovery approach can affect market position.
    Sams-Dodd F
    Drug Discov Today; 2007 Apr; 12(7-8):314-8. PubMed ID: 17395091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative design for improved therapeutic proteins.
    Desjarlais JR; Lazar GA
    Trends Biotechnol; 2003 Oct; 21(10):425-7. PubMed ID: 14512227
    [No Abstract]   [Full Text] [Related]  

  • 12. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragmentary solutions. Astex therapeutics puts the pieces together.
    Wolfson W
    Chem Biol; 2006 Aug; 13(8):799-801. PubMed ID: 16931326
    [No Abstract]   [Full Text] [Related]  

  • 14. The long and winding road.
    Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges and opportunities for non-antibody scaffold drugs.
    Vazquez-Lombardi R; Phan TG; Zimmermann C; Lowe D; Jermutus L; Christ D
    Drug Discov Today; 2015 Oct; 20(10):1271-83. PubMed ID: 26360055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.
    Larrick JW; Parren P; Huston JS; Plückthun A; Bradbury A; Tomlinson IM; Chester KA; Burton DR; Adams GP; Weiner LM; Scott JK; Alfenito MR; Veldman T; Reichert JM
    MAbs; 2014; 6(5):1115-23. PubMed ID: 25517297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody production.
    Birch JR; Racher AJ
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):671-85. PubMed ID: 16822577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Discovery and Development Asia-Pacific Conference 2005. Strategies and case studies of successful alliances, licensing and outsourcing partnerships.
    Alger L
    IDrugs; 2005 Aug; 8(8):639-41. PubMed ID: 16044371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer action means better drug: tuning up protein therapeutics.
    Szlachcic A; Zakrzewska M; Otlewski J
    Biotechnol Adv; 2011; 29(4):436-41. PubMed ID: 21443940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.